Immunoexpression Analysis and Prognostic Value of BLCAP in Breast Cancer

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Gromova, Irina ^a,b   Gromov, Pavel ^a,b   Kroman, Niels ^c   Wielenga, Vera Timmermans ^b,c   Simon, Ronald ^d   Sauter, Guido ^d   Moreira, José M A ^a,b,e  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Institute of Cancer Biolog   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER ASSOCIATED PROTEIN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TISSUE SECTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; CYTOPLASM; DENMARK; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84866668201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045967     Document Type: Article

References (45)

1. Celis JE, Gromov P, (2003) Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3: 9-15.
2. Celis JE, Gromov P, Gromova I, Moreira J M, Cabezón T, et al. (2003) Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research. Mol Cell Proteomics 2: 369-377.
3. Celis JE, Gromova I, Moreira JM, Cabezon T, Gromov P, (2004) Impact of proteomics on bladder cancer research. Pharmacogenomics 5: 381-394.
4. Celis JE, Moreira JM, Gromova I, Cabezón T, Ralfkiaer U, et al. (2005) Towards discovery-driven translational research in breast cancer. FEBS J 272: 2-15.
5. Gromov P, Moreira JM, Gromova I, Celis JE, (2008) Proteomic strategies in bladder cancer: From tissue to fluid and back. Proteomics Clin Appl 2: 974-988.
6. Østergaard M, Rasmussen HH, Nielsen HV, Vorum H, Ørntoft TF, et al. (1997) Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res. 57: 4111-4117.
7. Gromova I, Gromov P, Wolf H, Celis JE, (1998) Protein abundancy and mRNA levels of the adipocyte type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas. Int J Oncol 13: 379-383.
8. Østergaard M, Wolf H, Ørntoft TF, Celis JE, (1999) Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 20: 349-354.
9. Moreira JM, Gromov P, Celis JE, (2004) Expression of the tumor suppressor protein 14-3-3σ is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition. Mol Cell Proteomics 3: 410-419.
10. Celis JE, Celis P, Palsdottir H, Østergaard M, Gromov P, et al. (2002) Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics 1: 269-279.
11. Gromova I, Gromov P, Celis JE, (2002) Bc10: A novel human bladder cancer-associated protein with a conserved genomic structure downregulated in invasive cancer. Int J Cancer 98: 539-546.
12. Ohlsson G, Moreira JMA, Gromov P, Sauter G, Celis JE, (2005) Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics 4: 570-581.
13. Moreira JM, Ohlsson G, Gromov P, Simon R, Sauter G, et al. (2010) Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics 9: 161-177.
14. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, et al. (2007) Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol 1: 321-349.
15. Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, et al. (2009) Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort. Mol Oncol 3: 220-237.
16. Gromov P, Gromova I, Friis E, Timmermans-Wielenga V, Rank F, et al. (2010) Proteomic profiling of mammary carcinomas identifies C7orf24, a gamma-glutamyl cyclotransferase, as a potential cancer biomarker. J Proteome Res. 9: 3941-3953.
17. Celis JE, Gromov, P. Cabezón T, Moreira JM, Ambartsumian N, et al. (2004) Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 3: 327-344.
18. Gromov P, Gromova I, Bunkenborg J, Cabezón T, Moreira JM, et al. (2010) Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol 4: 65-89.
19. Zuo Z, Zhao M, Liu J, Gao G, Wu X, (2006) Functional analysis of bladder cancer-related protein gene: a putative cervical cancer tumor suppressor gene in cervical carcinoma. Tumour Biol 27: 221-226.
20. Rae FK, Stephenson SA, Nicol DL, Clements JA, (2000) Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 88: 726-732.
21. Yao J, Duan L, Fan M, Yuan J, Wu X, (2007) Overexpression of BLCAP induces S phase arrest and apoptosis independent of p53 and NF-kappaB in human tongue carcinoma: BLCAP overexpression induces S phase arrest and apoptosis. Mol Cell Biochem 297: 81-92.
22. Su HC, Zhao YH, Fan DG, Fan QY, Zhang P, et al. (2003) Relationship between expression of BLCAP protein and malignancy of osteosarcoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19: 465-466.
23. Daino K, Ugolin N, Altmeyer-Morel S, Guilly MN, Chevillard S, (2009) Gene expression profiling of alpha-radiation-induced rat osteosarcomas: identification of dysregulated genes involved in radiation-induced tumorigenesis of bone. Int J Cancer 125: 612-620.
24. Fan DG, Zhao F, Ding Y, Wu MM, Fan QY, et al. (2011) BLCAP induces apoptosis in human Ewing's sarcoma cells. Exp Biol Med 236: 1030-1035.
25. Zuo ZH, Zhao M, Liu J, Wei Y, Wu XX, (2006) Inhibitory effect of bladder cancer related protein gene on HeLa cell proliferation. Ai Zheng 25: 811-817.
26. Galeano F, Leroy A, Rossetti C, Gromova I, Gautier P, et al. (2010) Human BLCAP transcript: new editing events in normal and cancerous tissues. Int J Cancer 127: 127-137.
27. Levanon EY, Hallegger M, Kinar Y, Shemesh R, Djinovic-Carugo K, et al. (2005) Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res 33: 1162-1168.
28. Clutterbuck DR, Leroy A, O'Connell MA, Semple CA, (2005) A bioinformatic screen for novel A-I RNA editing sites reveals recoding editing in BC10. Bioinformatics 21: 2590-2595.
29. Riedmann EM, Schopoff S, Hartner JC, Jantsch MF, (2008) Specificity of ADAR-mediated RNA editing in newly identified targets. RNA 14: 1110-1118.
30. Allred DC, (2011) Molecular Biomarkers of Risk in Premalignancy and Breast Cancer Prevention. Cancer Prev Res 4: 1947-1952.
31. Cole K, Tabernero M, Anderson KS, (2011) Biologic characteristics of premalignant breast disease. Cancer Biomark 9: 177-192.
32. Misek DE, Kim EH, (2011) Protein biomarkers for the early detection of breast cancer. Int J Proteomics. 2011: 343582.
33. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, et al. (2010) Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 136: 1079-88.
34. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, et al. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 3609-14.
35. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, et al. (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15: 6987-92.
36. Birkhahn M, Mitra AP, Cote RJ, (2007) Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 7: 1717-27.
37. Jain KK, (2008) Innovations, challenges and future prospects of oncoproteomics. Mol Oncol 2: 153-60.
38. Bichsel VE, Liotta LA, Petricoin EF 3rd (2001) Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 7: 69-78.
39. Whiteley GR, (2006) Proteomic patterns for cancer diagnosis-promise and challenges. Mol Biosyst 2: 358-63.
40. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, et al. (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93: 1054-1061.
41. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, et al. (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-8540.
42. Elston CW, Ellis IO, (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-10.
43. Moreira JM, Cabezón T, Gromova I, Gromov P, Timmermans-Wielenga V, et al. (2010) Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. Mol Oncol 4: 539-361.
44. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, et al. (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358: 2107-2116.
45. Lukk M, Kapushesky M, Nikkilä J, Parkinson H, Goncalves A, et al. (2010) A global map of human gene expression. Nature Biotechnology 28: 322-24.